Author

Oliver SaOliver Sartorrtor

Tulane University - Cited by 42,078 - prostate cancer

Biography

Oliver SaOliver Sartorrtor is working in Tulane University School of Medicine, New Orleans, Louisiana, USA. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests reflect in his wide range of publications in various national and international journals.
Title
Cited by
Year
Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant …
NW Clarke, AJ Armstrong, A Thiery-Vuillemin, M Oya, ND Shore, ...Journal of Clinical Oncology 41 (6_suppl), LBA16-LBA16, 2023202
15
2023
Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment …
S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ...European urology 83 (3), 267-293, 2023202
10
2023
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment …
K Rahbar, M Essler, KM Pabst, M Eiber, C la Fougère, V Prasad, ...Journal of Nuclear Medicine 64 (4), 74-78, 2023202
5
2023
Prostate specific membrane antigen binding radiopharmaceuticals: current data and new concepts
O Sartor, A BaghianFrontiers in Medicine 9, 1060922, 2022202
4
2022
Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
A Jang, AT Kendi, O SartorTherapeutic Advances in Medical Oncology 15, 17588359231157632, 2023202
4
2023
Health-related quality of life and pain outcomes with [177Lu] Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant …
K Fizazi, K Herrmann, BJ Krause, K Rahbar, KN Chi, MJ Morris, O Sartor, ...The Lancet Oncology 2 (6), 597-610, 2023202
4
2023
Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC …
S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi, ND James, N Mottet, ...European Journal of Cancer 185, 178-215, 20220
3
2023
PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
B Ramnaraign, O SartorThe Oncologist 8 (5), 39-401, 030
2
2023
Next Generation Radiotheranostics Promoting Precision Medicine
KL Pomykala, BA Hadaschik, O Sartor, S Gillessen, CJ Sweeney, ...Annals of Oncology, 030
2
2023
The Value of Phenotypic Precision Medicine in Prostate Cancer
NM Hawkey, A Broderick, DJ George, O Sartor, AJ ArmstrongThe Oncologist 8 (), 93-104, 030
2
2023
Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with …
AJ Armstrong, VYT Liu, RR Selvaraju, E Chen, J Simko, S DeVries, ...Journal of Clinical Oncology 41 (16_suppl), 5001-5001, 030
2
2023
Localized prostate cancer—then and now
O SartorNew England Journal of Medicine 388 (7), 67-68, 2023202
1
2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
N Beije, W Abida, ES Antonarakis, E Castro, R de Wit, K Fizazi, ...European Urology, S0302-2838 (23) 0276, 2023202
1
2023
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 052 TrialO Sartor, TG Karrison, HM Sandler, LG Gomella, MB Amin, J Purdy, ...European urology, 2023202
1
2023
Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
CS Higano, DJ George, ND Shore, O Sartor, K Miller, PS Conti, ...Eclinicalmedicine 60, 2023202
1
2023
Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
CT Su, E Nizialek, JE Berchuck, PJ Vlachostergios, R Ashkar, A Sokolova, ...The Prostate 83 (3), 227-236, 2023202
1
2023
Phase I study of niraparib in combination with radium-223 for the treatment of metastatic castrate-resistant prostate cancer
Z Quinn, B Leiby, G Sonpavde, AD Choudhury, C Sweeney, D Einstein, ...Clinical Cancer Research 29 (), 50-59, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=SJ5QaPUAAAAJ&hl=en

Cited by
Citations 42078
h-index 94
i10-index 389
Recommended Journals
Open Access Journals